92 related articles for article (PubMed ID: 30626561)
1. Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.
Sayar H; Cripe LD; Saliba AN; Abu Zaid M; Konig H; Boswell HS
Leuk Res; 2019 Feb; 77():30-33. PubMed ID: 30626561
[No Abstract] [Full Text] [Related]
2. Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Walker AR; Wang H; Walsh K; Bhatnagar B; Vasu S; Garzon R; Canning R; Geyer S; Wu YZ; Devine SM; Klisovic R; Blum W; Marcucci G
Leuk Lymphoma; 2016 Sep; 57(9):2100-8. PubMed ID: 26784138
[TBL] [Abstract][Full Text] [Related]
3. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Macdonald DA; Assouline SE; Brandwein J; Kamel-Reid S; Eisenhauer EA; Couban S; Caplan S; Foo A; Walsh W; Leber B
Leuk Lymphoma; 2013 Apr; 54(4):760-6. PubMed ID: 23061485
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Becktell K; Houser K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e38-e40. PubMed ID: 29668549
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.
Østgård LS; Nørgaard M; Sengeløv H; Medeiros BC; Kjeldsen L; Overgaard UM; Severinsen MT; Marcher CW; Jensen MK; Nørgaard JM
Oncotarget; 2016 Nov; 7(44):72044-72056. PubMed ID: 27732947
[TBL] [Abstract][Full Text] [Related]
8. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
9. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
Press KR; Uy N; Keefer J; Gore SD; Carraway HE; Sakoian S; Prebet T
Leuk Lymphoma; 2018 Mar; 59(3):755-757. PubMed ID: 28738707
[No Abstract] [Full Text] [Related]
11. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Serve H; Krug U; Wagner R; Sauerland MC; Heinecke A; Brunnberg U; Schaich M; Ottmann O; Duyster J; Wandt H; Fischer T; Giagounidis A; Neubauer A; Reichle A; Aulitzky W; Noppeney R; Blau I; Kunzmann V; Stuhlmann R; Krämer A; Kreuzer KA; Brandts C; Steffen B; Thiede C; Müller-Tidow C; Ehninger G; Berdel WE
J Clin Oncol; 2013 Sep; 31(25):3110-8. PubMed ID: 23897964
[TBL] [Abstract][Full Text] [Related]
13. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton CB; Ravandi F
Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.
Nagarajan R; Gerbing R; Alonzo T; Johnston DL; Aplenc R; Kolb EA; Meshinchi S; Barakat LP; Sung L
Cancer Med; 2019 Aug; 8(9):4454-4464. PubMed ID: 31190442
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Galanis E; Anderson SK; Miller CR; Sarkaria JN; Jaeckle K; Buckner JC; Ligon KL; Ballman KV; Moore DF; Nebozhyn M; Loboda A; Schiff D; Ahluwalia MS; Lee EQ; Gerstner ER; Lesser GJ; Prados M; Grossman SA; Cerhan J; Giannini C; Wen PY;
Neuro Oncol; 2018 Mar; 20(4):546-556. PubMed ID: 29016887
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
17. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
18. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
Montalban-Bravo G; Huang X; Naqvi K; Jabbour E; Borthakur G; DiNardo CD; Pemmaraju N; Cortes J; Verstovsek S; Kadia T; Daver N; Wierda W; Alvarado Y; Konopleva M; Ravandi F; Estrov Z; Jain N; Alfonso A; Brandt M; Sneed T; Chen HC; Yang H; Bueso-Ramos C; Pierce S; Estey E; Bohannan Z; Kantarjian HM; Garcia-Manero G
Leukemia; 2017 Feb; 31(2):318-324. PubMed ID: 27795561
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]